Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

NRXPBullishCorporate Developmentsnews

High materiality9/10

FDA Submission for Abbreviated New Drug Application; $750 Million Market for Suicidal Depression Market Awaits Preservative-Free IV Ketamine: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)

Dec 2, 2025, 2:27 PM EST1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

NRXP's recent FDA filing and market potential for KETAFREE™ enhance attractiveness, reminiscent of breakthroughs in other biotech firms like CRISPR Therapeutics during their regulatory approvals.

AI summary

What happened, with direct paths to the underlying reporting

NRXP develops NRX-101 for treatment-resistant bipolar depression. FDA received NRXP's ANDA for KETAFREE™, target goal date July 29, 2026. Current ketamine market valued at $750 million, KETAFREE™ aims to disrupt. NRXP expanding clinical operations with multiple facilities in Florida. D. Boral research sets a $34 price target for NRXP.

NRXP develops NRX-101 for treatment-resistant bipolar depression.
FDA received NRXP's ANDA for KETAFREE™, target goal date July 29, 2026.
Current ketamine market valued at $750 million, KETAFREE™ aims to disrupt.
NRXP expanding clinical operations with multiple facilities in Florida.
D. Boral research sets a $34 price target for NRXP.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

FDA Submission for Abbreviated New Drug Application; $750 Million Market for Suicidal Depression Market Awaits Preservative-Free IV Ketamine: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)

NRx Pharmaceuticals Set to Report Q1 Earnings with Positive Developments

More Than 1 Million Suicidal Depression Cases Per Year May Be Treated by 2030 via New Indication for Augmentation of Transcranial Magnetic Stimulation: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)

Three Revenue-Generating Facilities in Florida Plus Six More by Year-End in Expanding $750 Million Market Suicidal Depression Market: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)